Skip to main content
. Author manuscript; available in PMC: 2016 Jul 28.
Published in final edited form as: Cancer Cell. 2015 Jun 25;28(1):42–56. doi: 10.1016/j.ccell.2015.05.007

Figure 6. SR9243 Inhibits Tumor Growth and Lipogenesis without Hepatotoxicity or Inflammation.

Figure 6

(A) Volume of mouse Lewis lung carcinoma (LLC1) syngeneic tumors implanted in C57BL6/J mice treated with vehicle (n = 8) or 60 mg/kg SR9243 (n = 8).

(B and C) RT-PCR analysis of (B) Srebp1c, Fasn, and (C) Pfk2 expression in tumors from mice treated with SR9243 or vehicle.

(D) Total body weight of tumor-bearing mice treated with SR9243.

(E) Serological analysis of blood glucose levels in vehicle and SR9243-treated mice.

(F) RT-PCR analysis showing expression of the cytokine Tnfα in livers and LLC1 tumors of C57BL6J mice treated with SR9243. See also Figure S5.

(G) Plasma levels of total cholesterol (CHOL), triglycerides (TRIG), low-density lipoproteins (LDL), and high-density lipoproteins (HDL) in vehicle and SR9243 (60 mg//kg)-treated mice.

(H) Plasma levels of the liver transaminases aspartate transaminase (AST), alkaline phosphatase (ALP), and alanine aminotransferase (ALT) as well as total albumin (ALB) in vehicle and SR9243-treated tumor-bearing mice. All RT-PCR and serological data were analyzed using a two-tailed t test followed by Bonferroni post-test. *p < 0.05. Error bars represent ±SEM. See also Figure S6.